ClinicalTrials.gg
RecruitingNCT06128746Updated Sep 28, 2026

rTMS Treatment of Spasticity in Children With Cerebral Palsy/ Hemiplegia Due to ABI - a RCT

An interventional study of Repetitive Transcranial Magnetic Stimulation and Sham Repetitive Transcranial Magnetic Stimulation in CP (Cerebral Palsy), sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by The University of Hong Kong · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Sep 28, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
4 Years to 18 Years
Sex
All
01

Study summary

This RCT aims to investigate the effect of repetitive transcranial magnatic stimulation (rTMS) in treating children with hemiplegoc cerebral palsy. The study will measure any improvement in spasticity after using contra-lesional inhibitory rTMS follow by intensive limb training.

Participants will attend a 10-day rTMS treatment sessions, follow by intensive training of the impaired limb. They will also undergo MRI scans before and after the treatment to investiagte the underlying neurophysiological mechanisms that lead to changes clinically by using TMS as well as MR-DKI. Researchers will compare the intervention group and the sham group to see if rTMS could result in improvement of participants' spasticity.

Read the detailed description

Cerebral palsy is the most common cause of lifelong physical disability in childhood, with an estimated prevalence of 1.5 per 1000 living biths for primary school-aged children. Spasticity is the most common symptoms in children with cerebral palsy, leading to muscle weakness affecting gross motor functions and causing complications such as pain, contracture and subluzation which will lead to inability to perform activity-based training and subsequently lead to further muscle weakness. Standard therapy with regular physiotherapy and occupational therapy are essential but time-consuming and the effects might not last for longer duration. Patients or caregivers decline medications because of side effects drowsiness while other interventions such as intra-thecal baclofen pump, rhizotomy or surgery are invasive.

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that has the ability to modulate excitation of the motor cortex area of the brain. There were past studies suggesting that using contralesional inhibitory rTMS was safe and feasible for patients with paediatric subcortical stroke and seemed to improve hand function in patients with hemiparesis. However, limited studies have been published on the effects of rTMS on improving spasticity in children with cerebral palsy. Hence, the objective of this study is to use low-frequency rTMS to the contra-lesional hemisphere in children with hemiplegic cerebral palsy to investigate if rTMS follow by intensive limb training would improve spasiticity of these children and whether the improvement can be sustained for a longer time. The underlying mechanisms that lead to the changes clinically will also be investigated by TMS and MRI.

02

Conditions studied

  • CP (Cerebral Palsy)

Keywords

  • TMS
  • Cerebral palsy
  • Spasticity
03

In context

Cerebral Palsy

1,939 studies on the registry are indexed under Cerebral Palsy; 457 are open to participants now.

This study's planned enrollment of 20 is below the median of 34 across 1,432 interventional studies indexed under Cerebral Palsy.

Browse Cerebral Palsy studies →

Lead sponsor

The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Sep 28, 2026. See what changed

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 4 years and 18 years
  • Diagnosis of hemiplegia
  • Upper limb spasticity ≥ 1
  • IQ ≥ 50

Exclusion criteria

Exclusion Criteria:

  • Any to rTMS
  • Severe spasticity (score of 4 or more in Ashworth scale)
  • Uncontrollable epilepsy
  • History of Botulinum toxin A injection in previous 6 months
  • Upper limb casting in previous 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Interventional rTMS group

    The intervention group will receive 1 Hz active rTMS during treatment, lasting for 20 minutes, follow up by 1.5 hours of motor training.

    Device: Repetitive Transcranial Magnetic Stimulation

  • Sham comparator
    Sham rTMS group

    The sham group will not receive any Hz of rTMS during treatment, also lasting for 20 minutes with 1.5 hours of motor training.

    Device: Sham Repetitive Transcranial Magnetic Stimulation

Interventions

  • DeviceRepetitive Transcranial Magnetic Stimulation

    1 Hz rTMS treatment for 20 mins, followed by 1.5 hours of motor training.

  • DeviceSham Repetitive Transcranial Magnetic Stimulation

    Sham Hz rTMS treatment for 20 mins, followed by 1.5 hours of motor training.

06

What researchers measure

Primary outcomes

  1. Modified Ashworth Scale

    Clinical measure of spasticity. Scores range from 0 to 4, with a higher score indicate worse in muscle tone

    Time frame: Baseline, Day 10, 17 of intervention and 2 months post intervention

  2. The range of motion scores

    ROM of thumb adduction, wrist dorsal flexion and extension, and elbow dorsal flexion and extension. Patients' range of motion score will be compared to the normative values

    Time frame: Baseline, Day 10, 17 of intervention and 2 months post intervention

  3. The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2)

    The BOT-2 provides a comprehensive overview of fine and gross motor skills in children and young adults within school age-range.

    Time frame: Baseline, Day 10, 17 of intervention and 2 months post intervention

Secondary outcomes

  1. Gross motor function measure

    Changes in motor function. A 4-point Likert scale with higher score indicates better motor function

    Time frame: Baseline, Day 10, 17 of intervention and 2 months post intervention

  2. Pediatric Quality of Life Cerebral Palsy module

    Quality of life measurement. Scores range from 0 to 100 with higher score indicate better quality of life.

    Time frame: Baseline, Day 10, 17 of intervention and 2 months post intervention

  3. MRI Brain: fMRI and DKI

    Functional MRI and Diffusion Kurtosis Imaging measuring the brain microstructural changes and structural connectivity during the intervention

    Time frame: Baseline, Day 10, 17 of intervention and 2 months post intervention

  4. Purdue Pegboard Test

    A standardized evaluation tool used to measure gross movements of hands, fingers, and arms, as well as fine fingertip dexterity.

    Time frame: Baseline, Day 10, 17 of intervention and 2 months post intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2029, 71 months after the start.

Of 903 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 71 months is above that.

Counting every sponsor, half of 922 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion May 2026 → Dec 2029 and completion Aug 2026 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 13, 2023
StartActual
Jan 13, 2024
Primary completionEst.
Dec 2029was May 2026
CompletionEst.
Dec 2029was Aug 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 2026→Dec 2029
Sep 28, 2026
Study completion
Aug 2026→Dec 2029
Sep 28, 2026
Eligibility
Minimum age 7 Years→4 Years; 2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedPatients aged between 74 years and 18 years
  • EditedDiagnosis of cerebral palsy with hemiplegia
Sep 28, 2026
Primary outcomes
2 time frame changed, 1 added
What changed in the outcomes
  • AddedThe Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2)Time frame: Baseline, Day 10, 17 of intervention and 2 months post intervention
  • Time frameModified Ashworth ScaleDay 10, 17 of intervention and 2 months post intervention → Baseline, Day 10, 17 of intervention and 2 months post intervention
  • Time frameThe range of motion scoresDay 10, 17 of intervention and 2 months post intervention → Baseline, Day 10, 17 of intervention and 2 months post intervention
Sep 28, 2026
Secondary outcomes
3 time frame changed, 1 added, 3 removed
What changed in the outcomes
  • AddedPurdue Pegboard TestTime frame: Baseline, Day 10, 17 of intervention and 2 months post intervention
  • RemovedZancolli scaleTime frame: Day 10, 17 of intervention and 2 months post intervention
  • RemovedHouse functional classification scaleTime frame: Day 10, 17 of intervention and 2 months post intervention
  • RemovedAssisting hand assessmentTime frame: Day 10, 17 of intervention and 2 months post intervention
  • Time frameGross motor function measureDay 10, 17 of intervention and 2 months post intervention → Baseline, Day 10, 17 of intervention and 2 months post intervention
  • Time framePediatric Quality of Life Cerebral Palsy moduleDay 10, 17 of intervention and 2 months post intervention → Baseline, Day 10, 17 of intervention and 2 months post intervention
  • Time frameMRI Brain: fMRI and DKIDay 10, 17 of intervention and 2 months post intervention → Baseline, Day 10, 17 of intervention and 2 months post intervention
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Primary completion May 2026→Dec 2029
    Study completion Aug 2026→Dec 2029
    Eligibility Minimum age 7 Years→4 Years; 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients aged between 74 years and 18 years
    • EditedDiagnosis of cerebral palsy with hemiplegia
    Primary outcomes 2 time frame changed, 1 added
    What changed in the outcomes
    • AddedThe Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2)Time frame: Baseline, Day 10, 17 of intervention and 2 months post intervention
    • Time frameModified Ashworth ScaleDay 10, 17 of intervention and 2 months post intervention → Baseline, Day 10, 17 of intervention and 2 months post intervention
    • Time frameThe range of motion scoresDay 10, 17 of intervention and 2 months post intervention → Baseline, Day 10, 17 of intervention and 2 months post intervention
    Secondary outcomes 3 time frame changed, 1 added, 3 removed
    What changed in the outcomes
    • AddedPurdue Pegboard TestTime frame: Baseline, Day 10, 17 of intervention and 2 months post intervention
    • RemovedZancolli scaleTime frame: Day 10, 17 of intervention and 2 months post intervention
    • RemovedHouse functional classification scaleTime frame: Day 10, 17 of intervention and 2 months post intervention
    • RemovedAssisting hand assessmentTime frame: Day 10, 17 of intervention and 2 months post intervention
    • Time frameGross motor function measureDay 10, 17 of intervention and 2 months post intervention → Baseline, Day 10, 17 of intervention and 2 months post intervention
    • Time framePediatric Quality of Life Cerebral Palsy moduleDay 10, 17 of intervention and 2 months post intervention → Baseline, Day 10, 17 of intervention and 2 months post intervention
    • Time frameMRI Brain: fMRI and DKIDay 10, 17 of intervention and 2 months post intervention → Baseline, Day 10, 17 of intervention and 2 months post intervention
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06128746
Responsible party
Winnie Wan Yee Tso (Dr) (Clinical Associate Professor, The University of Hong Kong) — Principal investigator
First posted
Nov 13, 2023
Start date
Jan 13, 2024
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Sep 28, 2026

Study contacts

Winnie Wan Yee Tso, MBBS
Contact
wytso@hku.hk
+85222554295
Chai Yin Charlie Fan, MPhil, OTR
Contact
charliefan@connect.hku.hk
+85222554375

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion